Study Stopped
The goal of collecting proof-of-concept information was met through additional modeling studies, new published evidence and information collected from the study
Deep Brain Stimulation Effects Study
1 other identifier
interventional
6
1 country
1
Brief Summary
The purpose of this study is to provide proof-of-concept that the test product can perform as intended in an intra-operative setting and the responses to the test product are perceivable in a person. The study will also compare results of the test product to the commercially-available product. Hypothesis: the test product will elicit successful test results in over 90% of test product.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_1
Started Apr 2010
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 25, 2010
CompletedStudy Start
First participant enrolled
April 1, 2010
CompletedFirst Posted
Study publicly available on registry
April 2, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2011
CompletedAugust 2, 2013
August 1, 2013
1.6 years
March 25, 2010
August 1, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
The HFR0001 device can elicit distinct intra-operative responses in subject symptoms.
Responses include testing parameters and symptom effects
9 months
Secondary Outcomes (1)
Adverse events that occur with the acute implantation and intra-operative testing of the study device.
9 months.
Study Arms (1)
Study device arm
EXPERIMENTALInterventions
Study device will be tested for up to 2 hours prior to chronic device implant.
Eligibility Criteria
You may qualify if:
- Subject is indicated for Activa® DBS implant for the treatment of Parkinson's disease and scheduled for surgery at the study site.
- Subject is willing to sign the informed consent to participate in the study.
- Subject is 18 years of age or older.
- Subject is a male or non-pregnant female.
- Subject has no factors that would put the subject at an additional risk for intra-operative or postoperative bleeding. This includes underlying disorders of the coagulation cascade (eg, hemophilia), disorders that affect platelet count or function (eg, Von Willebrand's disease), as well as administration of any anti-platelet or anti-coagulant medication in the 7 days prior to surgery, or any history of anticoagulant or aspirin use, that in the view of the neurosurgeon or neurologist would place the subject at an increased risk for intra-operative or postoperative bleeding.
You may not qualify if:
- Subject is indicated for DBS for treating a disorder other than Parkinson's disease.
- Subject has any medical contraindications to undergoing DBS surgery, (eg, infection, coagulopathy, or significant cardiac or other medical risk factors for surgery).
- Subject has a history of hemorrhagic stroke.
- Subject has a history of a neurosurgical ablation procedure.
- Subject is currently enrolled in or plans to enroll in any concurrent study that may confound the results of this study, as determined by the investigator or Medtronic.
- Subject has a diagnosis of acute myocardial infarction or cardiac arrest less than or equal to 6 months prior to the screening testing.
- Subject has a history of a seizure disorder
- Subject requires short surgery time due to general health issues, as determined by the investigator.
- Subject is a woman who is pregnant or planning to become pregnant, or a woman of child-bearing potential, who is not using a medically-acceptable method of birth control. Women of child-bearing potential must undergo a pregnancy test, with a clear negative result, no more than 7 days prior to the investigational procedure visit.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- MedtronicNeurolead
Study Sites (1)
Christian Albrechts University of Kiel
Kiel, D-24105, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
H. Maximilian Mehdorn, MD, PhD
University Clinics Kiel, Department of Neurosurgery
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 25, 2010
First Posted
April 2, 2010
Study Start
April 1, 2010
Primary Completion
November 1, 2011
Study Completion
November 1, 2011
Last Updated
August 2, 2013
Record last verified: 2013-08